Efficacy and safety of Shengjiang Xiexin decoction on irinotecan-induced diarrhea in small cell lung cancer patients: a multicenter, randomized, double-blind, placebo-controlled trial

• Main Authors: Chao Deng (Author), Qing Liu (Author), Meng Yang (Author), Hui-juan Cui (Author), Yang Ge (Author), Qin Li (Author), Shi-jie Zhu (Author), Guo-wang Yang (Author), Zhi-guo Zhang (Author), Yu Gao (Author), Yan-ni Lou (Author), Li-qun Jia (Author)
• Format: Book
• Published: BMC, 2024-11-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Background Irinotecan is a standard chemotherapeutic agent in small cell lung cancer (SCLC), however, as a common adverse reaction, diarrhea limits the use of irinotecan. Shengjiang Xiexin decoction (SXD) has been used in various gastrointestinal diseases in China two thousand years ago. We...